Daniel Agardh1, Hye-Seung Lee2, Kalle Kurppa3, Ville Simell4, Carin Andrén Aronsson5, Ola Jörneus5, Michael Hummel6, Edwin Liu7, Sibylle Koletzko8. 1. The Diabetes and Celiac Disease Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden; Pediatric Epidemiology Center, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Florida; daniel.agardh@med.lu.se. 2. Pediatric Epidemiology Center, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Florida; 3. Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland; 4. Department of Pediatrics, Turku University Hospital, Turku, Finland; 5. The Diabetes and Celiac Disease Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden; 6. Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum Rechts der Isar, Technische Universität München, and Forschergruppe Diabetes e.V., Neuherberg, Germany; 7. Digestive Health Institute, University of Colorado, Children's Hospital Colorado, Denver, Colorado; and. 8. Dr von Hauner Children's Hospital, Ludwig Maximilian University, Munich, Germany.
Abstract
OBJECTIVES: To investigate clinical features of celiac disease (CD) and their association with risk factors for CD in a genetic risk birth cohort. METHODS: Children from 6 clinical centers in 4 countries positive for HLA-DR3-DQ2 or DR4-DQ8 were annually screened for tissue transglutaminase antibodies (tTGA) and assessed for symptoms by questionnaires. Associations of symptoms with anthropometrics, known risk factors for CD, tTGA levels, and mucosal lesions in those biopsied were examined. RESULTS: Of 6706 screened children, 914 developed persistent positive tTGA, 406 underwent biopsies, and 340 had CD. Compared with age-matched tTGA-negative children, those with persistent tTGA were more likely to have symptoms at 2 (34% vs 19%, P < .001) and 3 years of age (28% vs 19%, P = .009) but not at 4 years (27% vs 21%, NS). Z-scores for height, weight, and BMI did not differ between groups. In children with persistent tTGA, having ≥ 1 symptom was associated with family history of CD (odds ratio = 2.59, 95% confidence interval, 1.21-5.57) but not with age, gender, or HLA-DR3-DQ2 homozygosity. At seroconversion, tTGA levels were higher in symptomatic than asymptomatic children (P < .001), in those from CD families (P < .001), and in US participants (P < .001) but not associated with age, gender, or HLA genotype. tTGA levels correlated with severity of mucosal lesions both in symptomatic (r = 0.53, P < .001) and asymptomatic children (r = 0.22, P = .01). CONCLUSIONS: A majority of children detected with persistent tTGA in screenings are asymptomatic and have normal growth by age 4 years. tTGA levels correlate more strongly with severity of mucosal lesions in symptomatic as compared with asymptomatic children.
OBJECTIVES: To investigate clinical features of celiac disease (CD) and their association with risk factors for CD in a genetic risk birth cohort. METHODS: Children from 6 clinical centers in 4 countries positive for HLA-DR3-DQ2 or DR4-DQ8 were annually screened for tissue transglutaminase antibodies (tTGA) and assessed for symptoms by questionnaires. Associations of symptoms with anthropometrics, known risk factors for CD, tTGA levels, and mucosal lesions in those biopsied were examined. RESULTS: Of 6706 screened children, 914 developed persistent positive tTGA, 406 underwent biopsies, and 340 had CD. Compared with age-matched tTGA-negative children, those with persistent tTGA were more likely to have symptoms at 2 (34% vs 19%, P < .001) and 3 years of age (28% vs 19%, P = .009) but not at 4 years (27% vs 21%, NS). Z-scores for height, weight, and BMI did not differ between groups. In children with persistent tTGA, having ≥ 1 symptom was associated with family history of CD (odds ratio = 2.59, 95% confidence interval, 1.21-5.57) but not with age, gender, or HLA-DR3-DQ2 homozygosity. At seroconversion, tTGA levels were higher in symptomatic than asymptomatic children (P < .001), in those from CD families (P < .001), and in US participants (P < .001) but not associated with age, gender, or HLA genotype. tTGA levels correlated with severity of mucosal lesions both in symptomatic (r = 0.53, P < .001) and asymptomatic children (r = 0.22, P = .01). CONCLUSIONS: A majority of children detected with persistent tTGA in screenings are asymptomatic and have normal growth by age 4 years. tTGA levels correlate more strongly with severity of mucosal lesions in symptomatic as compared with asymptomatic children.
Authors: Michael A D'Amico; Jessica Holmes; Stavros N Stavropoulos; Marisa Frederick; Joseph Levy; Amy R DeFelice; Philip G Kazlow; Peter H R Green Journal: Clin Pediatr (Phila) Date: 2005-04 Impact factor: 1.168
Authors: M Esteve; M Rosinach; F Fernández-Bañares; C Farré; A Salas; M Alsina; P Vilar; A Abad-Lacruz; M Forné; M Mariné; R Santaolalla; J C Espinós; J M Viver Journal: Gut Date: 2006-05-18 Impact factor: 23.059
Authors: Paul Zubillaga; Maria Concepcion Vidales; Itziar Zubillaga; Victor Ormaechea; Nerea García-Urkía; Juan Carlos Vitoria Journal: J Pediatr Gastroenterol Nutr Date: 2002-05 Impact factor: 2.839
Authors: Päivi A Pynnönen; Erkki T Isometsä; Matti A Verkasalo; Seppo A Kähkönen; Ilkka Sipilä; Erkki Savilahti; Veikko A Aalberg Journal: BMC Psychiatry Date: 2005-03-17 Impact factor: 3.630
Authors: Edwin Liu; Fran Dong; Anna E Barón; Iman Taki; Jill M Norris; Brigitte I Frohnert; Edward J Hoffenberg; Marian Rewers Journal: Gastroenterology Date: 2017-02-07 Impact factor: 22.682
Authors: Marisa G Stahl; Fran Dong; Molly M Lamb; Kathleen C Waugh; Iman Taki; Ketil Størdal; Lars C Stene; Marian J Rewers; Edwin Liu; Jill M Norris; Karl Mårild Journal: Scand J Gastroenterol Date: 2020-09-17 Impact factor: 2.423
Authors: Carin Andrén Aronsson; Hye-Seung Lee; Elin M Hård Af Segerstad; Ulla Uusitalo; Jimin Yang; Sibylle Koletzko; Edwin Liu; Kalle Kurppa; Polly J Bingley; Jorma Toppari; Anette G Ziegler; Jin-Xiong She; William A Hagopian; Marian Rewers; Beena Akolkar; Jeffrey P Krischer; Suvi M Virtanen; Jill M Norris; Daniel Agardh Journal: JAMA Date: 2019-08-13 Impact factor: 56.272
Authors: Martin W Laass; Roma Schmitz; Holm H Uhlig; Klaus-Peter Zimmer; Michael Thamm; Sibylle Koletzko Journal: Dtsch Arztebl Int Date: 2015-08-17 Impact factor: 5.594
Authors: Laura B Smith; Kristian F Lynch; Kalle Kurppa; Sibylle Koletzko; Jeffrey Krischer; Edwin Liu; Suzanne Bennett Johnson; Daniel Agardh Journal: Pediatrics Date: 2017-02-20 Impact factor: 9.703
Authors: Sibylle Koletzko; Hye-Seung Lee; Andreas Beyerlein; Carin A Aronsson; Michael Hummel; Edwin Liu; Ville Simell; Kalle Kurppa; Åke Lernmark; William Hagopian; Marian Rewers; Jin-Xiong She; Olli Simell; Jorma Toppari; Anette-G Ziegler; Jeffrey Krischer; Daniel Agardh Journal: J Pediatr Gastroenterol Nutr Date: 2018-03 Impact factor: 3.288
Authors: William Hagopian; Hye-Seung Lee; Edwin Liu; Marian Rewers; Jin-Xiong She; Anette-G Ziegler; Åke Lernmark; Jorma Toppari; Stephen S Rich; Jeffrey P Krischer; Henry Erlich; Beena Akolkar; Daniel Agardh Journal: Pediatrics Date: 2017-10-10 Impact factor: 9.703